From: Using Mendelian randomization study to assess the renal effects of antihypertensive drugs
Class | #SNPs | Beta | 95% CI | p |
---|---|---|---|---|
ACE inhibitors | 1 | 0.06 | 0.008, 0.11 | 0.02 |
ARBs | 1 | −0.02 | − 0.10, 0.06 | 0.65 |
CCBs | 9 | −0.0001 | −0.03, 0.03 | 0.99 |
Alpha-adrenoceptor blockers | 6 | −0.004 | −0.03, 0.02 | 0.73 |
Adrenergic neuron blockers | 3 | −0.01 | −0.06, 0.03 | 0.61 |
Beta-adrenoceptor blockers | 7 | −0.02 | −0.04, − 0.004 | 0.02 |
Centrally acting antihypertensives | 4 | −0.01 | −0.09, 0.07 | 0.86 |
Loop diuretics | 2 | 0.05 | 0.004, 0.09 | 0.03 |
PSDs and aldosterone antagonists | 4 | −0.03 | −0.07, 0.005 | 0.09 |
Renin inhibitors | 1 | −0.003 | −0.07, 0.06 | 0.92 |
Thiazides and related diuretics | 4 | −0.03 | −0.08, 0.01 | 0.12 |
Vasodilator antihypertensives | 8 | −0.01 | −0.03, 0.02 | 0.57 |